Curcumin reduces trabecular and cortical bone in naïve and lewis lung carcinoma-bearing mice

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3153-3162

  Yan, Lin ^a   Yee, John A ^b   Cao, Jay ^a  

^a GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Curcumin; Mice; Morphometrics; Remodeling

Indexed keywords

CURCUMIN; OSTEOCALCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BONE MASS; BONE REMODELING; CALORIC INTAKE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORTICAL BONE; DIET SUPPLEMENTATION; FEMALE; FEMUR; LEAN BODY WEIGHT; LEWIS CARCINOMA; METASTASIS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRABECULAR BONE; VERTEBRA BODY;

BONE; CURCUMIN; MICE; MORPHOMETRICS; REMODELING;

ACID PHOSPHATASE; ANIMALS; BODY COMPOSITION; BODY WEIGHT; BONE AND BONES; CARCINOMA, LEWIS LUNG; CURCUMIN; DIETARY SUPPLEMENTS; ENERGY INTAKE; FEMALE; FEMUR; ISOENZYMES; MICE; MICE, INBRED C57BL; OSTEOCALCIN; SPINE;

EID: 84883283417     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Satoskar RR, Shah SJ and Shenoy SG: Evaluation of antiinflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 24: 651-654, 1986.
2. Masuda T, Maekawa T, Hidaka K, Bando H, Takeda Y and Yamaguchi H: Chemical studies on antioxidant mechanism of curcumin: analysis of oxidative coupling products from curcumin and linoleate. J Agric Food Chem 49: 2539-2547, 2001.
3. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L and Sakariah KK: Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 47: 4297-4300, 1999.
4. Inano H, Onoda M, Inafuku N, Kubota M, Kamada Y, Osawa T, Kobayashi H and Wakabayashi K: Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis 20: 1011-1018, 1999.
5. Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR and Conney AH: Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54: 5841-5847, 1994.
6. Yan L: Dietary supplementation with curcumin enhances metastatic growth of Lewis lung carcinoma in mice. Int J Cancer 132: 269-275, 2013.
7. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C and Chollet P: Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8-14, 2010.
8. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ and Steward WP: Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854, 2004.
9. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
10. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr. and Brenner DE: Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4: 354-364, 2012.
11. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900, 2001.
12. Ozaki K, Takeda H, Iwahashi H, Kitano S and Hanazawa S: NF-kB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 410: 297-300, 1997.
13. Bharti AC, Takada Y and Aggarwal BB: Curcumin (diferuloylmethane) inhibits receptor activator of NF-kB ligand-induced NF-kB activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172: 5940-5947, 2004.
14. Yang MW, Wang TH, Yan PP, Chu LW, Yu J, Gao ZD, Li YZ and Guo BL: Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine 18: 205-213, 2011.
15. Kim WK, Ke K, Sul OJ, Kim HJ, Kim SH, Lee MH, Kim HJ, Kim SY, Chung HT and Choi HS: Curcumin protects against ovariectomy-induced bone loss and decreases osteoclastogenesis. J Cell Biochem 112: 3159-3166, 2011.
16. French DL, Muir JM and Webber CE: The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin. Phytomedicine 15: 1069-1078, 2008.
17. Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington, D.C.: National Academies Press, 2011.
18. Reeves PG, Nielsen FH and Fahey GCJ: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition Ad Hoc Writing Committee on the reformulation of the AIN-76A rodent diet. J Nutr 123: 1939-1951, 1993.
19. Weinreb M, Shinar D and Rodan GA: Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res 5: 831-842, 1990.
20. Boivin G, Morel G, Lian JB, Anthoine-Terrier C, Dubois PM and Meunier PJ: Localization of endogenous osteocalcin in neonatal rat bone and its absence in articular cartilage: Effect of warfarin treatment. Virchows Arch A Pathol Anat Histopathol 417: 505-512, 1990.
21. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC and Meunier PJ: Serum bone Gla-protein: A specific marker for bone formation in postmenopausal osteoporosis. Lancet 1: 1091-1093, 1984.
22. Brown JP, Delmas PD, Arlot M and Meunier PJ: Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 64: 954-959, 1987.
23. Pastoureau P, Meunier PJ and Delmas PD: Serum osteocalcin (bone Gla-protein), an index of bone growth in lambs. Comparison with age-related histomorphometric changes. Bone 12: 143-149, 1991.
24. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ and Vaananen H: K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15: 1337-1345, 2000.
25. Kirstein B, Chambers TJ and Fuller K: Secretion of tartrateresistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem 98: 1085-1094, 2006.
26. Ballanti P, Minisola S, Pacitti MT, Scarnecchia L, Rosso R, Mazzuoli GF and Bonucci E: Tartrate-resistant acid phosphate activity as osteoclastic marker: Sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int 7: 39-43, 1997.
27. Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S and Vaananen HK: Serum tartrateresistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71: 20-25, 2002.
28. Chappard D, Libouban H, Legrand E, Ifrah N, Masson C, Basle MF and Audran M: Computed microtomography of bone specimens for rapid analysis of bone changes associated with malignancy. Anat Rec (Hoboken) 293: 1125-1133, 2010.
29. Blouin S, Moreau MF, Basle MF and Chappard D: Relations between radiograph texture analysis and microcomputed tomography in two rat models of bone metastases. Cells Tissues Organs 182: 182-192, 2006.
30. Mundy GR: Metastatic bone disease. In: Bone Remodeling and Its Disorders, Second Edition. London: Martin Dunitz, pp. 123-146, 1999.
31. Aldridge SE, Lennard TW, Williams JR and Birch, MA: Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer 92: 1531-1537, 2005.
32. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M and Hakeda Y: Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473: 161-164, 2000.
33. Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M and Kuramoto A: Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factorinduced bone resorption. Blood 75: 715-720, 1990.
34. Hie M, Yamazaki M and Tsukamoto I: Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes. Eur J Pharmacol 621: 1-9, 2009.
35. Folwarczna J, Zych M and Trzeciak HI: Effects of curcumin on the skeletal system in rats. Pharmacol Rep 62: 900-909, 2010.
36. Barve A, Khor TO, Hao X, Keum YS, Yang CS, Reddy B and Kong AN: Murine prostate cancer inhibition by dietary phytochemicals-curcumin and phenyethylisothiocyanate. Pharm Res 25: 2181-2189, 2008.
37. Lee JC, Kinniry PA, Arguiri E, Serota M, Kanterakis S, Chatterjee S, Solomides CC, Javvadi P, Koumenis C, Cengel KA and Christofidou-Solomidou M: Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat Res 173: 590-601, 2010.
38. National Toxicology Program. NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 427: 1-275, 1993.
39. Dance-Barnes ST, Kock ND, Moore JE, Lin EY, Mosley LJ, D'Agostino RB Jr, McCoy TP, Townsend AJ and Miller MS: Lung tumor promotion by curcumin. Carcinogenesis 30: 1016-1023, 2009.
40. Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A and Lopez-Lazaro M: The dark side of curcumin. Int J Cancer 126: 1771-1775, 2010.
41. USDA. USDA National Nutrient Database for Standard Reference, Release 23. 2010.